

# Quality Improvement Guidelines for Transjugular Intrahepatic Portosystemic Shunts

Sean R. Dariushnia, MD, Ziv J Haskal, MD, Mehran Midia, MD, FRCPC, Louis G. Martin, MD, T. Gregory Walker, MD, Sanjeeva P. Kalva, MD, Timothy W.I. Clark, MD, Suvranu Ganguli, MD, Venkataramu Krishnamurthy, MD, Cindy K. Saiter, NP, and Boris Nikolic, MD, MBA  
(for the Society of Interventional Radiology Standards of Practice Committee)

## ABBREVIATIONS

HE = hepatic encephalopathy, TIPS = transjugular intrahepatic portosystemic shunt

## PREAMBLE

The membership of the Society of Interventional Radiology (SIR) Standards of Practice Committee represents experts in a broad spectrum of interventional procedures from the private and academic sectors of medicine. Generally, Standards of Practice Committee members dedicate the vast majority of their professional time to performing interventional procedures; as such, they represent a valid, broad expert constituency on the subject matter under consideration for standards production.

## METHODOLOGY

SIR produces its Standards of Practice documents using the following process. Standards documents of relevance and timeliness are conceptualized by the Standards of Practice Committee members. A

From the Department of Radiology, Interventional Radiology and Image-Guided Medicine (S.R.D.), Emory University School of Medicine, Atlanta, Georgia; Department of Radiology and Medical Imaging (Z.J.H.), University of Virginia, Charlottesville, Virginia; Department of Diagnostic Imaging (M.M.), McMaster University, Hamilton, Ontario, Canada; Department of Radiology (L.G.M.), Emory University Hospital, Atlanta, Georgia; Division of Vascular Imaging and Intervention (T.G.W.), Massachusetts General Hospital; Department of Radiology and Center for Image Guided Cancer Therapy (S.G.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Division of Interventional Radiology, Department of Radiology (S.P.K.), University of Texas Southwestern Medical Center, Dallas, Texas; Section of Interventional Radiology (T.W.I.C.), Penn Presbyterian Medical Center, Philadelphia, Pennsylvania; Department of Radiology, Division of Vascular and Interventional Radiology (V.K.), University of Michigan Medical Center, Ann Arbor, Michigan; Radiology Associates (C.K.S.), Pensacola, Florida; and Department of Radiology (B.N.), Stratton Medical Center, Albany, New York. Received September 15, 2015; final revision received and accepted September 25, 2015. Address correspondence to S.R.D., c/o SIR, 3975 Fair Ridge Dr., Suite 400 N., Fairfax, VA 22033; E-mail: [dariushnia1@yahoo.com](mailto:dariushnia1@yahoo.com)

S.P.K. received royalties from Springer (Berlin, Germany) and Elsevier (Philadelphia, PA), as well as personal fees from Celanova Biosciences (San Antonio, TX) and the Koo Foundation (Taipei, Taiwan). None of the other authors have identified a conflict of interest.

Earlier versions of this article appeared in *J Vasc Interv Radiol* 2001; 12(2):131–136; and *J Vasc Interv Radiol* 2003; 14(9 part 2):S265–S270.

© SIR, 2016

*J Vasc Interv Radiol* 2016; 27:1–7

<http://dx.doi.org/10.1016/j.jvir.2015.09.018>

recognized expert is identified to serve as the principal author for the document. Additional authors may be assigned depending on the magnitude of the project.

An in-depth literature search is performed with use of electronic medical literature databases. Then, a critical review of peer-reviewed articles is performed regarding the study methodology, results, and conclusions. The qualitative weight of these articles is assembled into an evidence table, which is used to write the document such that it contains evidence-based data with respect to content, rates, and thresholds.

When the evidence of literature is weak, conflicting, or contradictory, consensus for the parameter is reached by a minimum of 12 Standards of Practice Committee members using a modified Delphi consensus method (Appendix A). For the purpose of these documents, consensus is defined as 80% Delphi participant agreement on a value or parameter.

The draft document is critically reviewed by the Standards of Practice Committee members in a telephone conference call or face-to-face meeting. The finalized draft from the Committee is sent to the SIR membership for further input/criticism during a 30-day comment period. These comments are discussed by the Standards of Practice Committee, and appropriate revisions are made to create the finished standards document. Before its publication, the document is endorsed by the SIR Executive Council.

## INTRODUCTION

During the past decade, transjugular intrahepatic portosystemic shunt (TIPS) creation has been established as an effective treatment for variceal bleeding and refractory ascites. Since the 2003 Quality Improvement Guidelines for Transjugular Intrahepatic Portosystemic Shunts (1), numerous additional randomized controlled trials, systematic reviews, and meta-analyses have been published on TIPS creation. The technology of stents has evolved, with polytetrafluoroethylene-covered stents widely used. Moreover, the role interventional radiologists play in the management and complications of portal hypertension has also expanded. Therefore, this document was updated to reflect the foregoing points while emphasizing the current literature and outcomes.

## PRE-TIPS WORKUP

Workup for TIPS creation may include complete blood count, metabolic panel, liver function tests, and coagulation profile. Additionally, it is important to obtain cross-sectional imaging (to assess candidacy for the procedure, technical feasibility, and need for modified or advanced techniques), determine evidence of previous or

current hepatic decompensation (ie, ascites, encephalopathy, variceal bleeding, hypoxia, or congestive heart failure), and identify possible significant systemic comorbidities (2).

## CLINICAL OUTCOMES AND PROGNOSTIC FACTORS

Aside from procedure-related complications, clinical outcomes are most strongly determined by preprocedure status, including measures such as the Model for End-stage Liver Disease score and its modifications, Acute Physiology and Chronic Health Evaluation II score, and Emory score (3–10). In addition, patient age, urgency of the procedure, preprocedure hepatic venous pressure gradient, pre- and post-TIPS liver function test results (eg, serum bilirubin), right atrial pressure, and diastolic function have been shown to correlate with or predict survival after TIPS creation (11–15). Many of these factors are also predictors for the development of hepatic encephalopathy (HE) following TIPS creation. Other risks for HE may include age > 65 years, Child–Pugh score > 12, history of HE, placement of a large-diameter stent (> 10 mm), low corrected portosystemic gradient (< 5 mm Hg), and albumin level (16,17).

## TIPS CREATION

TIPS creation is a percutaneous image-guided procedure in which a decompressive channel is created between a hepatic vein and an intrahepatic branch of the portal vein to reduce portal vein pressure. Creation of a TIPS involves several steps:

1. Catheterization of the hepatic veins and performance of hepatic venography;
2. Passage of a long curved transjugular needle from the chosen hepatic vein through the liver parenchyma into an intrahepatic branch of the portal vein;
3. Direct measurement of the systemic and portal vein pressures through the transjugular access;
4. Balloon dilation of the tract between the hepatic and portal veins;
5. Deployment of a covered stent/stent graft or metallic (self-expanding) stent within the tract to maintain it against the recoil of the surrounding liver parenchyma; and
6. Variceal embolization when indicated.

Other technical descriptions for portosystemic shunt creation are beyond the scope of this document. However, direct intrahepatic portocaval shunt creation has been described as an alternate method, especially in patients with hepatic vein occlusion, portal vein thrombosis, or unfavorable hepatic/portal vein anatomy (18,19).

## CLINICAL AND IMAGING FOLLOW-UP AFTER TIPS CREATION

Interventional radiologists play an integral role in the care of the patient with a TIPS. Although many protocols have been described for noninvasive imaging follow-up, ultrasonography is a relatively inexpensive screening examination for shunt dysfunction after TIPS creation, and can be performed within 7–14 days after shunt creation and then at 3 months, 6 months, and every 6–12 months thereafter (20). If sonographic evaluation is not diagnostic and there is clinical concern for shunt dysfunction, further imaging with computed tomography or venography can be performed to assess shunt patency. Clinical and imaging follow-up may also be performed in tandem with hepatocellular screening.

Post-TIPS encephalopathy or liver failure may require shunt reduction. Participation by the interventional radiologist in patient follow-up with the anticipation of post-TIPS complications can help

facilitate further intervention, or, if needed, referral to a tertiary hospital if more advanced intervention is necessary.

The present guidelines were developed for use in institution-wide quality-improvement programs to assess the practice of diagnostic arteriography. The most important processes of care are (i) patient selection, (ii) performance of the procedure, and (iii) monitoring the patient. The major outcome measures for diagnostic arteriography include complete imaging of the pathologic process, success rates, and complication rates. Outcome measures are assigned threshold values.

Although practicing physicians should strive to achieve perfect outcomes (eg, 100% success, 0% complications), in practice, all physicians will fall short of this ideal to a variable extent. Therefore, in addition to quality-improvement case reviews customarily conducted after individual procedural failures or complications, outcome-measure thresholds should be used to assess diagnostic arteriography in ongoing quality-improvement programs. For the purpose of these guidelines, a threshold is specific level of an indicator that, when reached or crossed, should prompt a review of departmental policies and procedures. “Procedure thresholds” or “overall thresholds” reference a group of outcome measures for a procedure; for example, major complications for diagnostic arteriography. Individual complications may also be associated with complication-specific thresholds, such as fever or hemorrhage. When outcome measures such as success rates or indications decrease below a (minimum) threshold, or when complications rates exceed a (maximum) threshold, a departmental review should be performed to determine causes and to implement changes if necessary. Thresholds may vary from those listed here; for example, patient referral patterns may dictate a different threshold value for a particular indicator at a particular institution. Therefore, setting universal thresholds is very difficult, and each department is urged to alter the thresholds as needed to higher or lower values to meet its own quality-improvement program needs.

Complications can be stratified on the basis of outcome. Major complications may result in admission to a hospital for therapy (for outpatient procedures), an unplanned increase in the level of care, prolonged hospitalization, permanent adverse sequelae, or death. Minor complications result in no sequelae; they may require nominal therapy or a short hospital stay for observation, generally overnight (Appendix B). The complication rates and thresholds in this document refer to major complications unless otherwise noted.

Treatment measures (including clinical, hemodynamic, and anatomic success), patient descriptors, measures of shunt patency, and encephalopathy grading are described in the Reporting Standards for Transjugular Intrahepatic Portosystemic Shunts (21). These same definitions are incorporated into this document by reference.

## INDICATIONS

TIPS creation is indicated for the following (22–48):

1. Uncontrollable (ie, “rescue”) variceal hemorrhage;
2. Recurrent variceal hemorrhage despite endoscopic therapy;
3. Portal hypertensive gastropathy;
4. Refractory ascites;
5. Hepatic hydrothorax; and
6. Budd–Chiari syndrome.

TIPS creation may also be beneficial in the treatment of hepatorenal syndrome (49,50) and in patients with recurrent portal hypertension after liver transplantation, although the complexity of posttransplantation liver anatomy may make TIPS creation more challenging (51–56). There is also evidence that early TIPS creation may improve survival, and its indication may expand beyond that of a rescue therapy. A multicenter randomized controlled trial (23) in patients with Child–Pugh class B/C cirrhosis who presented with acute variceal bleeding and were initially treated with endoscopic and medical therapy and then randomized to undergo continued medical

therapy versus TIPS creation within 24–72 hours showed that patients who received a TIPS had a lower risk of recurrent bleeding, as well as improved survival with no increase in HE.

In addition to the aforementioned indications, TIPS creation has been described in patients with cirrhosis with bland portal vein thrombosis to achieve or maintain surgical transplantation candidacy. TIPS creation has also been performed before elective extrahepatic abdominal surgery to decrease morbidity and mortality (57–61). In native and transplanted livers, TIPS creation can be used adjunctively to treat splanchnic vein thrombosis (acute and chronic) and to obliterate ectopic varices (62–64). Palliative TIPS creation has been used in oncologic cases (patients with primary and metastatic liver tumors) to treat complications of portal hypertension and to allow completion of planned systemic therapies (65,66).

The threshold for these indications is 95%. When fewer than 95% of procedures are for these indications, the department will review the process of patient selection.

## CONTRAINDICATIONS

Although there are no absolute contraindications to TIPS creation, several relative contraindications exist. Creating a TIPS in patients with the following conditions is likely to increase the rates of procedural or TIPS-related complications:

1. Elevated right or left heart pressures;
2. Heart failure or severe cardiac valvular insufficiency;
3. Rapidly progressive liver failure;
4. Severe or uncontrolled HE;
5. Uncontrolled systemic infection or sepsis;
6. Unrelieved biliary obstruction;
7. Polycystic liver disease;
8. Extensive primary or metastatic hepatic malignancy; and
9. Severe, uncorrectable coagulopathy.

## MEASURES OF SUCCESS

Success should be classified as technical, hemodynamic, and clinical (21).

### Technical Success

Technical success describes the successful creation of a shunt between the hepatic vein and intrahepatic branch of the portal vein. In the case of parallel shunt creation, technical success is reported for individual shunts.

### Hemodynamic Success

Hemodynamic success refers to the successful post-TIPS reduction of the portosystemic gradient below a threshold indicated for the clinical setting. Some authors have reported that, in patients with bleeding varices, cessation of variceal filling during hand-injected splenic (or, in the case of intestinal varices, mesenteric) venography is a useful marker of successful decompression. This sign can be more difficult to standardize because different injection rates can lead to differences in the appearance of variceal flow. Although it can be argued that endoscopic confirmation of variceal decompression may be the gold standard for the confirmation of hemodynamic success, this is impractical and probably unnecessary. Hemodynamic success can also be reported at follow-up shunt revisions. Absolute portal and right atrial pressures and calculated portosystemic gradient (in millimeters of mercury) should be recorded at the start and completion of the procedure. The data should be reported as mean pressure  $\pm$  standard deviation.

### Clinical Success

TIPS creation is well-described as an effective treatment for variceal bleeding and refractory ascites. Although much has been written about

the unpredictable initial patency of TIPS, the long-term management of patients after their first episode of variceal bleeding will depend on the actual outcomes of differing treatments and on patients' Model for End-stage Liver Disease or Child–Pugh scores, not necessarily on the absolute patency of a TIPS. Therefore, clinical success is perhaps the most important parameter in longitudinal studies of patients with a TIPS.

In the case of active bleeding, which can be triaged according to the Baveno criteria (67), early clinical success is determined by prompt arrest of acute variceal hemorrhage. This is indicated by cessation of demonstrable gastrointestinal bleeding, transfusion requirements, pharmacologic support, balloon tamponade, and return of hemodynamic stability. Because nonvariceal bleeding can coexist in more than one third of patients with varices, it is essential to verify endoscopically the causes of continued or recurrent bleeding after shunt placement or revision.

Clinical success is also reflected in the interval of time during which the patient remains free of the symptoms alleviated by the TIPS. For patients treated for variceal hemorrhage, this is the period after TIPS creation until a bleeding episode recurs. For patients with ascites, this is the period between improvement or resolution of ascites and recurrence of ascites. This is best described in terms of “event-free survival” intervals after TIPS creation. For variceal bleeding, it is recognized that this measure will greatly underestimate shunt stenosis or occlusion because patients with a TIPS may remain asymptomatic for prolonged periods despite highly stenotic or occluded shunts.

Numerous prospective and retrospective studies have compared the use of expanded polytetrafluoroethylene-covered versus noncovered stents in the creation of TIPS. Covered stents confer a higher and longer patency rate, although improved overall survival remains to be established (68–79).

**Table 1.** Success Rates for TIPS Creation (22,23,25–27,31–33,37,38,80–83)

Type of Success	Rate (%)
Technical	
Creation of patent TIPS between hepatic vein and branch of portal vein*	95
Hemodynamic	
Reduction of portosystemic gradient to level targeted by operator <sup>†</sup>	95
Clinical	
Resolution of clinical indication for which procedure was performed	
Variceal bleeding (22,23,25–27)	> 90
Ascites (31–33,37,38,82,83) <sup>‡</sup>	55

TIPS = transjugular intrahepatic portosystemic shunt.

\*The technical complexity of TIPS creation may be challenging, especially in centers with lower-volume TIPS referrals, and, as a result, lower success rates may be encountered. Therefore, a single threshold is difficult to set, and departments may need to alter their thresholds as needed to higher or lower levels to meet their own quality-improvement program needs.

<sup>†</sup>In general, the target portosystemic gradient is  $\leq$  12 mm Hg for esophageal variceal bleeding (80,81). The authors recognize that the final portosystemic gradient for gastric variceal bleeding may require a different gradient threshold. Additionally, the final portosystemic gradient in patients with ascites may need to be lower than the threshold for bleeding varices.

<sup>‡</sup>The clinical success rates in the literature for ascites non-recurrence is broad, ranging from 55% to 80%, with the majority of studies reporting approximately 55%.

## SUCCESS RATES

Success rates for creation of a TIPS in patients with patent hepatic or portal veins are given in **Table 1** (22,23,25–27,31–33,37,38,80–83). Successful shunt creation has been reported in cases of hepatic vein thrombosis or obstruction (47,48,73,84–88), as well as portal vein thrombosis (even in patients with cavernous transformation) (58,62,89–92), and neither clinical presentation should be considered an absolute contraindication to TIPS creation. These situations are relatively infrequent and may require considerably more technical expertise than shunt creation would require in patients with patent portal and hepatic veins. Accordingly, it is recognized that lower success rates can be anticipated in patients with these anatomic conditions. However, it is presently difficult to define threshold levels for success in such cases.

## COMPLICATION RATES AND THRESHOLDS

Although major complications (16,93–105) can occur during or as a result of TIPS creation, they are generally uncommon and are reduced with increased operator experience (**Table 2**) (106–113).

Published rates for individual types of complications are highly dependent on patient selection and are based on series comprising several hundred patients, which is a volume larger than most individual practitioners are likely to treat. It is also recognized that a single complication can cause a rate to cross above a complication-specific threshold when the complication occurs in a small volume of patients (eg, early in a quality-improvement program). In this situation, the overall procedure threshold is more appropriate for use in a quality-improvement program.

The overall procedure threshold for major complications is 5.0%. The overall procedure threshold for major complications is determined by the following formula:

$$\frac{\text{Number of patients with complications undergoing diagnostic arteriography only} \times 100}{\text{number of patients undergoing TIPS creation only}}$$

## APPENDIX A. METHODOLOGY

Reported complication-specific rates in some cases reflect the aggregate of major and minor complications. Thresholds are derived from critical evaluation of the literature, evaluation of empirical data from Standards of Practice Committee Member practices, and, when available, the SIR HI-IQ System national database.

Consensus on statements in this document was obtained with use of a modified Delphi technique (114,115).

Technical documents specifying the exact consensus and literature review methodologies, as well as the institutional affiliations and professional credentials of the authors of this document, are available upon request from: SIR, 3975 Fair Ridge Dr., Suite 400 N., Fairfax, VA 22033.

## APPENDIX B. SIR STANDARDS OF PRACTICE COMMITTEE CLASSIFICATION OF COMPLICATIONS BY OUTCOME

### Minor Complications

- A. No therapy, no consequence; or
- B. Nominal therapy, no consequence; includes overnight admission for observation only.

### Major Complications

- C. Require therapy, minor hospitalization (< 48 h);
- D. Require major therapy, unplanned increase in level of care, prolonged hospitalization (> 48 h);

**Table 2.** Complication Rates and Thresholds (106–113)

Complication	Reported Rate (%)	Suggested Complication-Specific Threshold (%)
Major	3	5
Hemoperitoneum*	0.5	1
Biliary peritonitis	1	2
Stent malposition <sup>†</sup>	1	1
Hemobilia	2	2
Radiation skin burn	0.1	0.1
Hepatic infarction	0.5	0.5
Renal failure requiring chronic dialysis	0.25	0.5
Hepatic artery injury	1	2
Accelerated liver failure <sup>‡</sup>	3	–
Severe or controlled encephalopathy <sup>§</sup>	–	–
Death <sup>  </sup>	1	2
Minor	4	8
Transient contrast medium–induced renal failure	2	5
Encephalopathy controlled by medical therapy	15–25	15–25
Fever	2	5
Transient pulmonary edema	1	1
Entry site hematoma	2	5

Note—Appendix B describes classifications of complications. MELD = Model for End-stage Liver Disease; TIPS = transjugular intrahepatic portosystemic shunt.

\*Hemoperitoneum warranting blood transfusion or other directed interventions.

<sup>†</sup>A major stent malposition includes conditions such as free stent migration within the portal or systemic venous circulations or malposition resulting in vascular perforation.

<sup>‡</sup>The rate of accelerated liver failure after TIPS creation is highly dependent on patient selection, final shunt diameter, and comorbid factors such as preexisting multiple organ system failure, increased MELD scores, and high Child–Pugh scores. Part of this risk is not specific to the creation of a TIPS, but is shared by surgical forms of portosystemic diversion as well. As such, as specific threshold for this complication cannot be assigned.

<sup>§</sup>Encephalopathy rates are directly dependent upon patient selection, as with any form of portosystemic diversion. For example, patients with severe or refractory ascites may manifest severe encephalopathy (requiring hospitalization) in 30%–40% of cases (106) (107). In contrast, elective patients with Child–Pugh class A/B hepatocellular disease may manifest severe, uncontrolled encephalopathy in 3%–10% of cases (108–113).

<sup>||</sup>Death refers to 30-day mortality directly related to a complication of TIPS creation. As with accelerated liver failure after TIPS<sup>‡</sup>, the majority of deaths after TIPS are dependent upon preexisting comorbid factors such as elevated MELD scores, Child–Pugh scores, and multi-organ failure. The existence of these pre-TIPS conditions can greatly increase the rate of 30-day mortality after TIPS or surgical forms of portosystemic diversion. Proper patient selection and minimization of procedural complications can greatly reduce death rates.

- E. Have permanent adverse sequelae; or  
F. Result in death.

## ACKNOWLEDGMENTS

The majority of the work in this document is largely based on the 2003 Quality Improvement Guidelines for Transjugular Intrahepatic Portosystemic Shunts (1). The authors wish to recognize the great contributions the original authors made in drafting these guidelines. Sean R. Dariushnia, MD, authored the first draft of this document and served as topic leader during the subsequent revisions of the draft. Sean R. Dariushnia, MD, and James Silberzweig, MD, are co-chairs of the Revision Subcommittee. T. Gregory Walker, MD, is chair of the SIR Standards of Practice Committee. Boris Nikolic, MD, MBA, is Councilor of the SIR Standards Division. Other members of the Standards of Practice Committee and SIR who participated in the development of this clinical practice guideline are: Gunjan Aeron, MBBS, MD, J. Fritz Angle, MD, Ganesan Annamalai, MD, Ronald Arellano, MD, Sriharsha Athreya, MBBS, MS, FRCS, FRCR, Mark O. Baerlocher, MD, Stephen Balter, PhD, Kevin Baskin, MD, Ian Brennan, MD, Olga Brook, MD, Daniel B. Brown, MD, Drew Caplin, MD, Michael Censullo, MD, Abbas Chamsuddin, MD, Christine Chao, MD, Mandeeep S. Dagli, MD, Jon Davidson, MD, A. Devane, MD, Eduardo Eyheremendy, MD, Florian Fintelmann, MD, Joseph Gemmete, MD, Vyacheslav Gendel, MD, Jennifer Gould, MD, Tara Graham, MD, John Hancock, MD, Mark Hogan, MD, Eric Hohenwalter, MD, Bertrand Janne d'Othee, MD, MPH, Arshad Khan, MD, Hyun S. "Kevin" Kim, MD, Maureen Pearl Kohi, MD, Christy Lee, APN, Naganathan B. Mani, MD, Gloria Martinez-Salazar, MD, J. Kevin McGraw, MD, Philip Meyers, MD, Donald L. Miller, MD, Jason W. Mitchell, MD, Christopher Morris, MD, Indravadan Patel, MD, Anil Pillai, MD, Uei Pua, MD, Ellen Redstone, MD, Anne C. Roberts, MD, Tarun Sabharwal, MD, Marc Sapoval, MD, PhD, Brian J. Schiro, MD, Samir Shah, MD, Paul Shyn, MD, Siddhartha A. Padia, MD, Nasir Siddiqi, MD, James E. Silberzweig, MD, LeAnn Stokes, MD, Rajeev Suri, MD, Timothy Swan, MD, Ulku Turba, MD, Aradhana Venkatesan, MD, Jeffrey L. Weinstein, MD, and Joan C. Wojak, MD.

## REFERENCES

- Haskal ZJ, Martin L, Cardella JF, et al. Quality improvement guidelines for transjugular intrahepatic portosystemic shunts. *J Vasc Interv Radiol* 2003; 14:S265–S270.
- Im GY, Lubezky N, Facciuto ME, Schiano TD. Surgery in patients with portal hypertension: a preoperative checklist and strategies for attenuating risk. *Clin Liver Dis* 2014; 18:477–505.
- Durand F, Valla D. Assessment of prognosis of cirrhosis. *Semin Liver Dis* 2008; 28:110–122.
- Ferral H, Gamboa P, Postoak DW, et al. Survival after elective transjugular intrahepatic portosystemic shunt creation: prediction with model for end-stage liver disease score. *Radiology* 2004; 231:231–236.
- Gaba RC, Shah KD, Couture PM, et al. Within-patient temporal variance in MELD score and impact on survival prediction after TIPS creation. *Ann Hepatol* 2013; 12:797–802.
- Gaba RC, Couture PM, Bui JT, et al. Prognostic capability of different liver disease scoring systems for prediction of early mortality after transjugular intrahepatic portosystemic shunt creation. *J Vasc Interv Radiol* 2013; 24:411–420, 20 e1–e4; quiz 21.
- Goldberg DS, Olthoff KM. Standardizing MELD exceptions: current challenges and future directions. *Curr Transplant Rep* 2014; 1: 232–237.
- Reverter E, Tandon P, Augustin S, et al. A MELD-based model to determine risk of mortality among patients with acute variceal bleeding. *Gastroenterology* 2014; 146:412–419.e3.
- Orloff MJ, Vaida F, Isenberg JI, et al. Child-Turcotte score versus MELD for prognosis in a randomized controlled trial of emergency treatment of bleeding esophageal varices in cirrhosis. *J Surg Res* 2012; 178:139–146.
- Al Sibae MR, Cappell MS. Accuracy of MELD scores in predicting mortality in decompensated cirrhosis from variceal bleeding, hepatorenal syndrome, alcoholic hepatitis, or acute liver failure as well as mortality after non-transplant surgery or TIPS. *Dig Dis Sci* 2011; 56:977–987.
- Parvinian A, Shah KD, Couture PM, et al. Older patient age may predict early mortality after transjugular intrahepatic portosystemic shunt creation in individuals at intermediate risk. *J Vasc Interv Radiol* 2013; 24:941–946.
- Gazzera C, Righi D, Doriguzzi Breatta A, et al. Emergency transjugular intrahepatic portosystemic shunt (TIPS): results, complications and predictors of mortality in the first month of follow-up. *Radiol Med (Torino)* 2012; 117:46–53.
- Casadaban LC, Parvinian A, Couture PM, et al. Characterization of liver function parameter alterations after transjugular intrahepatic portosystemic shunt creation and association with early mortality. *AJR Am J Roentgenol* 2014; 203:1363–1370.
- Parvinian A, Bui JT, Knuttinen MG, Minocha J, Gaba RC. Right atrial pressure may impact early survival of patients undergoing transjugular intrahepatic portosystemic shunt creation. *Ann Hepatol* 2014; 13: 411–419.
- Rabie RN, Cazzaniga M, Salerno F, Wong F. The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. *Am J Gastroenterol* 2009; 104: 2458–2466.
- Bai M, Qi X, Yang Z, et al. Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: a systematic review. *J Gastroenterol Hepatol* 2011; 26:943–951.
- Casadaban LC, Parvinian A, Minocha J, et al. Clearing the confusion over hepatic encephalopathy after TIPS creation: incidence, prognostic factors, and clinical outcomes. *Dig Dis Sci* 2015; 60:1059–1066.
- Hoppe H, Wang SL, Petersen BD. Intravascular US-guided direct intrahepatic portocaval shunt with an expanded polytetrafluoroethylene-covered stent-graft. *Radiology* 2008; 246:306–314.
- Ward TJ, Techasith T, Louie JD, Hwang GL, Hofmann LV, Sze DY. Emergent salvage direct intrahepatic portocaval shunt procedure for acute variceal hemorrhage. *J Vasc Interv Radiol* 2015; 26:829–834.
- Lake D, Guimaraes M, Ackerman S, et al. Comparative results of Doppler sonography after TIPS using covered and bare stents. *AJR Am J Roentgenol* 2006; 186:1138–1143.
- Haskal ZJ, Rees CR, Ring EJ, Saxon R, Sacks D; Society of Interventional Radiology Technology Assessment Committee. Reporting standards for transjugular intrahepatic portosystemic shunts. *J Vasc Interv Radiol* 2003; 14:S419–S426.
- Cello JP, Ring EJ, Olcott EW, et al. Endoscopic sclerotherapy compared with percutaneous transjugular intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal hemorrhage. A randomized, controlled trial. *Ann Intern Med* 1997; 126:858–865.
- Garcia-Pagan JC, Caca K, Bureau C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. *N Engl J Med* 2010; 362: 2370–2379.
- Khan S, Tudur Smith C, Williamson P, Sutton R. Portosystemic shunts versus endoscopic therapy for variceal rebleeding in patients with cirrhosis. *Cochrane Database Syst Rev* 2006; CD000553.
- Qi X, Jia J, Bai M, et al. Transjugular intrahepatic portosystemic shunt for acute variceal bleeding: a meta-analysis. *J Clin Gastroenterol* 2014.
- Monescillo A, Martinez-Lagares F, Ruiz-del-Arbol L, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. *Hepatology* 2004; 40:793–801.
- Azoulay D, Castaing D, Majno P, et al. Salvage transjugular intrahepatic portosystemic shunt for uncontrolled variceal bleeding in patients with decompensated cirrhosis. *J Hepatol* 2001; 35:590–597.
- Zheng M, Chen Y, Bai J, et al. Transjugular intrahepatic portosystemic shunt versus endoscopic therapy in the secondary prophylaxis of variceal rebleeding in cirrhotic patients: meta-analysis update. *J Clin Gastroenterol* 2008; 42:507–516.
- Mezawa S, Homma H, Ohta H, et al. Effect of transjugular intrahepatic portosystemic shunt formation on portal hypertensive gastropathy and gastric circulation. *Am J Gastroenterol* 2001; 96:1155–1159.
- Urata J, Yamashita Y, Tsuchigame T, et al. The effects of transjugular intrahepatic portosystemic shunt on portal hypertensive gastropathy. *J Gastroenterol Hepatol* 1998; 13:1061–1067.
- Albillos A, Banares R, Gonzalez M, Catalina MV, Molinero LM. A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. *J Hepatol* 2005; 43:990–996.

32. Deltenre P, Mathurin P, Dharancy S, et al. Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta-analysis. *Liver Int* 2005; 25:349–356.
33. Lodato F, Berzigotti A, Lisotti A, et al. Transjugular intrahepatic portosystemic shunt placement for refractory ascites: a single-centre experience. *Scand J Gastroenterol* 2012; 47:1494–1500.
34. Nair S, Singh R, Yoselewitz M. Correlation between portal/hepatic vein gradient and response to transjugular intrahepatic portosystemic shunt creation in refractory ascites. *J Vasc Interv Radiol* 2004; 15:1431–1434.
35. Narahara Y, Kanazawa H, Fukuda T, et al. Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial. *J Gastroenterol* 2011; 46:78–85.
36. Saab S, Nieto JM, Lewis SK, Runyon BA. TIPS versus paracentesis for cirrhotic patients with refractory ascites. *Cochrane Database Syst Rev* 2006; CD004889.
37. Salerno F, Camma C, Enea M, Rossle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. *Gastroenterology* 2007; 133:825–834.
38. Thalheimer U, Leandro G, Samonakis DN, et al. TIPS for refractory ascites: a single-centre experience. *J Gastroenterol* 2009; 44:1089–1095.
39. Thuluvath PJ, Bal JS, Mitchell S, Lund G, Venbrux A. TIPS for management of refractory ascites: response and survival are both unpredictable. *Dig Dis Sci* 2003; 48:542–550.
40. Dhanasekaran R, West JK, Gonzales PC, et al. Transjugular intrahepatic portosystemic shunt for symptomatic refractory hepatic hydrothorax in patients with cirrhosis. *Am J Gastroenterol* 2010; 105:635–641.
41. Parvianian A, Gaba RC. Parallel TIPS for treatment of refractory ascites and hepatic hydrothorax. *Dig Dis Sci* 2013; 58:3052–3056.
42. Siegerstetter V, Deibert P, Ochs A, Olschewski M, Blum HE, Rossle M. Treatment of refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt: long-term results in 40 patients. *Eur J Gastroenterol Hepatol* 2001; 13:529–534.
43. Spencer EB, Cohen DT, Darcy MD. Safety and efficacy of transjugular intrahepatic portosystemic shunt creation for the treatment of hepatic hydrothorax. *J Vasc Interv Radiol* 2002; 13:385–390.
44. Wilputte JY, Goffette P, Zech F, Godoy-Gepert A, Geubel A. The outcome after transjugular intrahepatic portosystemic shunt (TIPS) for hepatic hydrothorax is closely related to liver dysfunction: a long-term study in 28 patients. *Acta Gastroenterol Belg* 2007; 70:6–10.
45. Qi X, Yang M, Fan D, Han G. Transjugular intrahepatic portosystemic shunt in the treatment of Budd-Chiari syndrome: a critical review of literatures. *Scand J Gastroenterol* 2013; 48:771–784.
46. Seijo S, Plessier A, Hoekstra J, et al. Good long-term outcome of Budd-Chiari syndrome with a step-wise management. *Hepatology* 2013; 57:1962–1968.
47. Garcia-Pagan JC, Heydtmann M, Raffa S, et al. TIPS for Budd-Chiari syndrome: long-term results and prognostic factors in 124 patients. *Gastroenterology* 2008; 135:808–815.
48. Khuroo MS, Al-Suhabani H, Al-Sebayel M, et al. Budd-Chiari syndrome: long-term effect on outcome with transjugular intrahepatic portosystemic shunt. *J Gastroenterol Hepatol* 2005; 20:1494–1502.
49. Anderson CL, Saad WE, Kalagher SD, et al. Effect of transjugular intrahepatic portosystemic shunt placement on renal function: a 7-year, single-center experience. *J Vasc Interv Radiol* 2010; 21:1370–1376.
50. Testino G, Ferro C, Sumberaz A, et al. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation. *Hepatogastroenterology* 2003; 50: 1753–1755.
51. Abouljoud M, Yoshida A, Kim D, et al. Transjugular intrahepatic portosystemic shunts for refractory ascites after liver transplantation. *Transplant Proc* 2005; 37:1248–1250.
52. Barbier L, Hardwigsen J, Borentain P, et al. Impact of transjugular intrahepatic portosystemic shunting on liver transplantation: 12-year single-center experience. *Clin Res Hepatol Gastroenterol* 2014; 38: 155–163.
53. Choi DX, Jain AB, Orloff MS. Utility of transjugular intrahepatic portosystemic shunts in liver-transplant recipients. *J Am Coll Surg* 2009; 208:539–546.
54. El Atrache M, Abouljoud M, Sharma S, et al. Transjugular intrahepatic portosystemic shunt following liver transplantation: can outcomes be predicted? *Clin Transplant* 2012; 26:657–661.
55. Finkenstedt A, Graziadei IW, Nachbaur K, et al. Transjugular intrahepatic portosystemic shunt in liver transplant recipients. *World J Gastroenterol* 2009; 15:1999–2004.
56. King A, Masterton G, Gunson B, et al. A case-controlled study of the safety and efficacy of transjugular intrahepatic portosystemic shunts after liver transplantation. *Liver Transpl* 2011; 17:771–778.
57. Habib A, Desai K, Hickey R, et al. Portal vein recanalization-transjugular intrahepatic portosystemic shunt using the transsplenic approach to achieve transplant candidacy in patients with chronic portal vein thrombosis. *J Vasc Interv Radiol* 2015; 26:499–506.
58. Luca A, Miraglia R, Caruso S, et al. Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis. *Gut* 2011; 60:846–852.
59. Deipolyi AR, Kalva SP, Oklu R, Walker TG, Wicky S, Ganguli S. Reduction in portal venous pressure by transjugular intrahepatic portosystemic shunt for treatment of hemorrhagic stomal varices. *AJR Am J Roentgenol* 2014; 203:668–673.
60. D'Avola D, Bilbao JI, Zozaya G, et al. Efficacy of transjugular intrahepatic portosystemic shunt to prevent total portal vein thrombosis in cirrhotic patients awaiting for liver transplantation. *Transplant Proc* 2012; 44:2603–2605.
61. Menahem B, Lubrano J, Desjouis A, Lepennec V, Lebreton G, Alves A. Transjugular intrahepatic portosystemic shunt placement increases feasibility of colorectal surgery in cirrhotic patients with severe portal hypertension. *Dig Liver Dis* 2015; 47:81–84.
62. Senzolo M, T MS, Rossetto V, et al. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. *Liver Int* 2012; 32:919–927.
63. Liu L, Zhao Y, Qi X, et al. Transjugular intrahepatic portosystemic shunt for symptomatic portal hypertension in hepatocellular carcinoma with portal vein tumor thrombosis. *Hepatol Res* 2014; 44:621–630.
64. Vidal V, Joly L, Perreault P, Bouchard L, Lafortune M, Pomier-Layrargues G. Usefulness of transjugular intrahepatic portosystemic shunt in the management of bleeding ectopic varices in cirrhotic patients. *Cardiovasc Intervent Radiol* 2006; 29:216–219.
65. Wallace MJ, Madoff DC, Ahrar K, Warneke CL. Transjugular intrahepatic portosystemic shunts: experience in the oncology setting. *Cancer* 2004; 101:337–345.
66. Bettinger D, Knuppel E, Euringer W, et al. Efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPSS) in 40 patients with hepatocellular carcinoma. *Aliment Pharmacol Ther* 2015; 41:126–136.
67. de Franchis R, Baveno VF. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. *J Hepatol* 2010; 53:762–768.
68. Barrio J, Ripoll C, Banares R, et al. Comparison of transjugular intrahepatic portosystemic shunt dysfunction in PTFE-covered stent-grafts versus bare stents. *Eur J Radiol* 2005; 55:120–124.
69. Bureau C, Garcia-Pagan JC, Otal P, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. *Gastroenterology* 2004; 126:469–475.
70. Bureau C, Pagan JC, Layrargues GP, et al. Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multi-centre study. *Liver Int* 2007; 27:742–747.
71. Darwish Murad S, Luong TK, Pattynama PM, Hansen BE, van Buuren HR, Janssen HL. Long-term outcome of a covered vs. uncovered transjugular intrahepatic portosystemic shunt in Budd-Chiari syndrome. *Liver Int* 2008; 28:249–256.
72. Gaba RC, Omene BO, Podczewski ES, et al. TIPS for treatment of variceal hemorrhage: clinical outcomes in 128 patients at a single institution over a 12-year period. *J Vasc Interv Radiol* 2012; 23:227–235.
73. Gandini R, Konda D, Simonetti G. Transjugular intrahepatic portosystemic shunt patency and clinical outcome in patients with Budd-Chiari syndrome: covered versus uncovered stents. *Radiology* 2006; 241:298–305.
74. Hernandez-Guerra M, Turnes J, Rubinstein P, et al. PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome. *Hepatology* 2004; 40:1197–1202.
75. Jung HS, Kalva SP, Greenfield AJ, et al. TIPS: comparison of shunt patency and clinical outcomes between bare stents and expanded polytetrafluoroethylene stent-grafts. *J Vasc Interv Radiol* 2009; 20:180–185.
76. Maleux G, Perez-Gutierrez NA, Evrard S, et al. Covered stents are better than uncovered stents for transjugular intrahepatic portosystemic shunts in cirrhotic patients with refractory ascites: a retrospective cohort study. *Acta Gastroenterol Belg* 2010; 73:336–341.

77. Sommer CM, Gockner TL, Stampfl U, et al. Technical and clinical outcome of transjugular intrahepatic portosystemic stent shunt: bare metal stents (BMS) versus viatorr stent-grafts (VSG). *J Hepatobiliary Pancreat Sci* 2012; 81:2273–2280.
78. Wu X, Ding W, Cao J, et al. Favorable clinical outcome using a covered stent following transjugular intrahepatic portosystemic shunt in patients with portal hypertension. *J Hepatobiliary Pancreat Sci* 2010; 17:701–708.
79. Yang Z, Han G, Wu Q, et al. Patency and clinical outcomes of transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stents versus bare stents: a meta-analysis. *J Gastroenterol Hepatol* 2010; 25:1718–1725.
80. Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. *Hepatology* 1985; 5:419–424.
81. Casado M, Bosch J, Garcia-Pagan JC, et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. *Gastroenterology* 1998; 114:1296–1303.
82. Rossle M, Ochs A, Gulberg V, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. *N Engl J Med* 2000; 342:1701–1707.
83. Sanyal AJ, Genning C, Reddy KR, et al. The North American study for the treatment of refractory ascites. *Gastroenterology* 2003; 124:634–641.
84. Corso R, Intotero M, Solcia M, Castoldi MC, Rampoldi A. Treatment of Budd-Chiari syndrome with transjugular intrahepatic portosystemic shunt (TIPS). *Radiol Med (Torino)* 2008; 113:727–738.
85. Kavanagh PM, Roberts J, Gibney R, Malone D, Hegarty J, McCormick PA. Acute Budd-Chiari syndrome with liver failure: the experience of a policy of initial interventional radiological treatment using transjugular intrahepatic portosystemic shunt. *J Gastroenterol Hepatol* 2004; 19:1135–1139.
86. Mancuso A, Watkinson A, Tibballs J, Patch D, Burroughs AK. Budd-Chiari syndrome with portal, splenic, and superior mesenteric vein thrombosis treated with TIPS: who dares wins. *Gut* 2003; 52:438.
87. Molmenti EP, Segev DL, Arepally A, et al. The utility of TIPS in the management of Budd-Chiari syndrome. *Ann Surg* 2005; 241: 978–981, discussion 82–83.
88. Zahn A, Gotthardt D, Weiss KH, et al. Budd-Chiari syndrome: long term success via hepatic decompression using transjugular intrahepatic porto-systemic shunt. *BMC Gastroenterol* 2010; 10:25.
89. Bauer J, Johnson S, Durham J, et al. The role of TIPS for portal vein patency in liver transplant patients with portal vein thrombosis. *Liver Transpl* 2006; 12:1544–1551.
90. Han G, Qi X, He C, et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis. *J Hepatol* 2011; 54:78–88.
91. Perarnau JM, Baju A, D'Alteroche L, Viguier J, Ayoub J. Feasibility and long-term evolution of TIPS in cirrhotic patients with portal thrombosis. *Eur J Gastroenterol Hepatol* 2010; 22:1093–1098.
92. Wils A, van der Linden E, van Hoek B, Pattynama PM. Transjugular intrahepatic portosystemic shunt in patients with chronic portal vein occlusion and cavernous transformation. *J Clin Gastroenterol* 2009; 43: 982–984.
93. Chung HH, Razavi MK, Sze DY, et al. Portosystemic pressure gradient during transjugular intrahepatic portosystemic shunt with Viatorr stent graft: what is the critical low threshold to avoid medically uncontrolled low pressure gradient related complications? *J Gastroenterol Hepatol* 2008; 23:95–101.
94. Fehervari I, Szonyi L, Fazakas J, Gerlei Z, Lazar I. TIPS stent migration into the heart with 6-year follow-up. *Ann Transplant* 2011; 16:109–112.
95. Hayashi PH, Mao J, Slater K, et al. Atrial septal perforation from TIPS stent migration. *J Vasc Interv Radiol* 2004; 15:629–632.
96. Leong S, Kok HK, Govender P, Torreggiani W. Reducing risk of transjugular intrahepatic portosystemic shunt using ultrasound guided single needle pass. *World J Gastroenterol* 2013; 19:3528–3530.
97. Liu K, Fan XX, Wang XL, He CS, Wu XJ. Delayed liver laceration following transjugular intrahepatic portosystemic shunt for portal hypertension. *World J Gastroenterol* 2012; 18:7405–7408.
98. Madoff DC, Wallace MJ, Ahrar K, Saxon RR. TIPS-related hepatic encephalopathy: management options with novel endovascular techniques. *Radiographics* 2004; 24:21–36; discussion 36–37.
99. Mamiya Y, Kanazawa H, Kimura Y, et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. *Hepatol Res* 2004; 30: 162–168.
100. Mizrahi M, Adar T, Shouval D, Bloom AI, Shibolet O. Endotipitis-persistent infection of transjugular intrahepatic portosystemic shunt: pathogenesis, clinical features and management. *Liver Int* 2010; 30:175–183.
101. Peter P, Andrej Z, Katarina SP, Manca G, Pavel S. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with recurrent variceal hemorrhage. *Gastroenterol Res Pract* 2013; 2013:398172.
102. Riggio O, Masini A, Efrati C, et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. *J Hepatol* 2005; 42:674–679.
103. Ripamonti R, Ferral H, Alonzo M, Patel NH. Transjugular intrahepatic portosystemic shunt-related complications and practical solutions. *Semin Interv Radiol* 2006; 23:165–176.
104. Vizzutti F, Arena U, Rega L, et al. Liver failure complicating segmental hepatic ischaemia induced by a PTFE-coated TIPS stent. *Gut* 2009; 58: 582–584.
105. Wendler C, Shoenberger JM, Mailhot T, Perera P. Transjugular Intrahepatic portosystemic shunt (TIPS) migration to the heart diagnosed by emergency department ultrasound. *West J Emerg Med* 2012; 13: 525–526.
106. Crenshaw WB, Gordon FD, McEniff NJ, et al. Severe ascites: efficacy of the transjugular intrahepatic portosystemic shunt in treatment. *Radiology* 1996; 200:185–192.
107. Ochs A, Rossle M, Haag K, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. *N Engl J Med* 1995; 332:1192–1197.
108. LaBerge JM, Somberg KA, Lake JR, et al. Two-year outcome following transjugular intrahepatic portosystemic shunt for variceal bleeding: results in 90 patients. *Gastroenterology* 1995; 108:1143–1151.
109. LaBerge JM, Ring EJ, Gordon RL, et al. Creation of transjugular intrahepatic portosystemic shunts with the wallstent endoprosthesis: results in 100 patients. *Radiology* 1993; 187:413–420.
110. Sanyal AJ, Freedman AM, Shiffman ML, Purdum PP 3rd, Luketic VA, Cheatham AK. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study. *Hepatology* 1994; 20:46–55.
111. Zuckerman DA, Darcy MD, Bocchini TP, Hildebolt CF. Encephalopathy after transjugular intrahepatic portosystemic shunting: analysis of incidence and potential risk factors. *AJR Am J Roentgenol* 1997; 169: 1727–1731.
112. Somberg KA, Riegler JL, LaBerge JM, et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts: incidence and risk factors. *Am J Gastroenterol* 1995; 90:549–555.
113. Nolte W, Wiltfang J, Schindler C, et al. Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations. *Hepatology* 1998; 28:1215–1225.
114. Fink A, Kosecoff J, Chassin M, Brook RH. Consensus methods: characteristics and guidelines for use. *Am J Public Health* 1984; 74:979–983.
115. Leape LL, Hilborne LH, Park RE, et al. The appropriateness of use of coronary artery bypass graft surgery in New York State. *JAMA* 1993; 269:753–760.

## SIR DISCLAIMER

The clinical practice guidelines of the Society of Interventional Radiology attempt to define practice principles that generally should assist in producing high quality medical care. These guidelines are voluntary and are not rules. A physician may deviate from these guidelines, as necessitated by the individual patient and available resources. These practice guidelines should not be deemed inclusive of all proper methods of care or exclusive of other methods of care that are reasonably directed towards the same result. Other sources of information may be used in conjunction with these principles to produce a process leading to high quality medical care. The ultimate judgment regarding the conduct of any specific procedure or course of management must be made by the physician, who should consider all circumstances relevant to the individual clinical situation. Adherence to the SIR Quality Improvement Program will not assure a successful outcome in every situation. It is prudent to document the rationale for any deviation from the suggested practice guidelines in the department policies and procedure manual or in the patient's medical record.